Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 2:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 4,611 matching trials from the local directory fallback.

Filters: Intervention: 1 Clear all

Conditions: Advanced Solid Tumor
Interventions: DB-1310, Osimertinib, Trastuzumab, capecitabine; Drug
Lead sponsor: DualityBio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 15
States / cities: Sacramento, California • Santa Monica, California • Coral Gables, Florida + 12 more

Conditions: Alzheimer Disease, Healthy
Interventions: Positron Emission Tomography (PET) using 11C-ER176 for TSPO and 18F-SMBT1 for MAO-B; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years to 90 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma
Interventions: All-Trans Retinoic Acid (ATRA) Dose 0, All-Trans Retinoic Acid (ATRA) Dose 1; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelodysplastic Syndromes
Interventions: Azacitidine Level 0, Azacitidine Level 1, Iadademstat Level 0, Iadademstat Level 1; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Psoriatic Arthritis, Spondyloarthritis, Axial
Interventions: Placebo, Upadacitinib 15 MG [Rinvoq]; Drug
Lead sponsor: CARE ARTHRITIS LTD.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Cleveland, Ohio • Portland, Oregon • Philadelphia, Pennsylvania

Conditions: CRC (Colorectal Cancer), Cancer Cachexia, Colorectal Cancer
Interventions: NGM120 Q4W, NGM120 Q8W, Placebo given; Drug
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 13
States / cities: Los Angeles, California • Santa Rosa, California • Margate, Florida + 9 more

Conditions: Chronic Kidney Disease Stage 3
Interventions: AION-301, Placebo; Biological · Drug
Lead sponsor: AION Healthspan, Inc.; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: ISB 2001; Drug
Lead sponsor: Ichnos Sciences SA; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 10
States / cities: Palo Alto, California • Miami, Florida • Atlanta, Georgia + 7 more

Conditions: Advanced Cancer, Breast Cancer, Breast Cancer Metastatic, CCNE1 Amplification, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Metastatic Cancer, Ovarian Cancer, Solid Tumor
Interventions: Abemaciclib, Fulvestrant, INX-315; Drug
Lead sponsor: Incyclix Bio; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 15
States / cities: Orlando, Florida • Atlanta, Georgia • Augusta, Georgia + 10 more

Conditions: Advanced Basal Cell Carcinoma
Interventions: Vismodegib 150 MG Oral Capsule; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Non Hodgkin's Lymphoma Refractory/Relapsed
Interventions: CD19t-haNK suspension, Cyclophosphamide, Fludarabine, N803, Rituximab; Biological · Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Newport Beach, California • Tyler, Texas

Conditions: Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml
Interventions: ELVN-001; Drug
Lead sponsor: Enliven Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: New York, New York • The Bronx, New York • Portland, Oregon + 1 more

Conditions: Atrial Fibrillation, Diabetes Mellitus
Interventions: Dapagliflozin 10Mg Tab, Placebo; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Peritoneal Carcinomatosis
Interventions: Mitomycin C, flat dose 40 mg, Mitomycin C, weight-based dose 12.5 mg/m2; Drug
Lead sponsor: Prakash Pandalai; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 2
States / cities: Lexington, Kentucky • Burlington, Vermont

Conditions: Endometrial Cancer
Interventions: Abemaciclib, Atezolizumab - 21 Day Cycle, Atezolizumab - 28 Day Cycle, Bevacizumab, Giredestrant, Inavolisib, Ipatasertib, Letrozole, Talazoparib, Tiragolumab, Trastuzumab emtansine; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 21
States / cities: Duarte, California • San Francisco, California • Washington D.C., District of Columbia + 18 more

Conditions: Body Composition, Muscle Health, Muscle Strength
Interventions: Dietary Supplement - Placebo, Geranylgeraniol (150 mg), Geranylgeraniol (300 mg); Dietary Supplement
Lead sponsor: Lindenwood University; Other
Eligibility: 30 Years to 60 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Tuberculosis, Pulmonary
Interventions: 18F-FAPI-74; Combination Product
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Fistula in Ano
Interventions: ECMT-100; Device
Lead sponsor: ECM Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Lebanon, New Hampshire • Pittsburgh, Pennsylvania

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Cyclophosphamide, Fludarabine, MSGV1-PSCA-8T28Z; Drug · Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Alcohol Use Disorder
Interventions: CMND-100; Drug
Lead sponsor: Clearmind Medicine Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: New Haven, Connecticut • Baltimore, Maryland

Conditions: Acneiform Eruption Due to Chemical, Paronychia, Xerosis Cutis
Interventions: HT-001 0.5% Topical Gel, HT-001 1% Topical Gel, HT-001 2% Topical Gel, HT-001 Placebo; Drug
Lead sponsor: Hoth Therapeutics, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 9
States / cities: Irvine, California • Orange, California • Miami, Florida + 6 more

Conditions: Chronic Granulomatous Disease-associated Colitis
Interventions: MTP 101-LF; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 10 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cytokines, Gingival Bleeding, Gingivitis, Microbiome, Plaque
Interventions: Distilled Water, Marketed Comparator 1, Marketed Comparator 2, Prototype Rinse 1, Prototype Rinse 2; Other
Lead sponsor: Kenvue Brands LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Somerville, Massachusetts

Conditions: Knee Osteoarthritis
Interventions: Topical Diclofenac gel 1%; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 50 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Sacramento, California

Search by objective public record fields.

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Selective PET Imaging of Astrocytes and Microglia in Alzheimer's Disease

ATRA and Carfilzomib in Plasma Cell Myeloma Patients

Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome

A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis

An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD)

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)

Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Dose-Response Impact of Geranylgeraniol (GG) Supplementation on Muscle Health

18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients

Study Evaluating the Safety and Efficacy of an ECM Hydrogel for the Treatment of Anorectal Fistulas

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects

Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis

Comparison of the Effects of Oral Hygiene Regimens on Clinical, Immunomodulatory, and Microbial Outcomes and Oral Tolerance in People With Gingivitis

The Effects of Patient and Visit Characteristics on Health Outcomes in Knee Osteoarthritis